CDC25 Phosphatase Inhibitors: An Update

Title: CDC25 Phosphatase Inhibitors: An Update

Volume: 12 Issue: 1

Author(s): A. Lavecchia, C. Di Giovanni and E. Novellino

Affiliation:

Keywords: Antiproliferative agents, cancer, CDC25 inhibitors, cell cycle, dual-specificity phosphatases, obesity, Parkinson's disease, Xenopus laevis, C-terminal, phosphorylation, thiazolopyrimidine, phenyldioxolane, mutagenesis

Abstract: The cell division cycle 25 (CDC25) family of proteins is a group of highly conserved dual-specificity phosphatases. They are key regulators of normal cell division and the cell response to DNA damage, and play a fundamental role in transitions between cell cycle phases during normal cell division, via the activation of CdK/cyclin complexes. Their abnormal expression, detected in a number of tumors, often correlated with a poor clinical prognosis, implies that their dysregulation is involved in malignant transformation. Thus, inhibition of these proteins represents an attractive therapeutic target in oncology, as evidenced from many patents and papers published on the subject in recent years. Hence, this review aims to provide an overview of recent developments in the field of CDC25 phosphatase inhibitor design since 2008.

Cite this article as:

Lavecchia A., Di Giovanni C. and Novellino E., CDC25 Phosphatase Inhibitors: An Update, Mini-Reviews in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/138955712798868940